Ontology highlight
ABSTRACT:
SUBMITTER: Meng A
PROVIDER: S-EPMC9298258 | biostudies-literature | 2022 Feb
REPOSITORIES: biostudies-literature
Meng Amy A Humeniuk Rita R Jürgensmeier Juliane M JM Hsueh Chia-Hsiang CH Matzkies Franziska F Grant Ethan E Truong Hoa H Billin Andrew N AN Yu Helen H Feng Joy J Kwan Ellen E Tarnowski Thomas T Nelson Cara H CH
Clinical pharmacology and therapeutics 20211027 2
Tirabrutinib is an irreversible, small-molecule Bruton's tyrosine kinase (BTK) inhibitor, which was approved in Japan (VELEXBRU) to treat B-cell malignancies and is in clinical development for inflammatory diseases. As an application of model-informed drug development, a semimechanistic pharmacokinetic/pharmacodynamic (PK/PD) model for irreversible BTK inhibition of tirabrutinib was developed to support dose selection in clinical development, based on clinical PK and BTK occupancy data from two ...[more]